N-ACETYLCYSTEINE 600mg. IP + ACEBROPHYLLINE 100mg. IP

A combination of bronchodilator and mucolytic that treats blockage, swelling, chest congestion, and irritation associated with bronchial asthma, chronic obstructive pulmonary disorder, and bronchitis. Blocks the release of certain chemicals (such as phosphodiesterase) in the respiratory tract that trigger airway inflammation, swelling, and narrowing. (Sumit Roy Tapadar, 2014) Facilitates bronchial muscle relaxation and reduces airway inflammation and obstruction. (Sumit Roy Tapadar, 2014) Reduces the viscosity of the sputum and the severity of coughing in patients with chronic bronchitis and COPD. (Dekhuijzen, 2006) Decreases the number of bacteria in the airways, the number and severity of influenza-like episodes, the number of exacerbations, and the number of readmissions. (Dekhuijzen, 2006) Alters the secretion of mucus and its physical properties which results in the improvement of mucociliary clearance. (Maciej Kupczyk, 2002) Reduces the rate of COPD exacerbations and improves airway functions. (Pierachille Santus, 2014) A potent therapeutically effective drug in patients with acute or chronic bronchitis, chronic obstructive or asthma-like bronchitis, and recurrence of chronic bronchitis. (Pozzi, 2007) A potent airway mucus regulator with an anti-inflammatory action that lessens the frequency of episodes of bronchial obstruction and improves indexes of ventilatory function. (Pozzi, 2007) A promising medication that cleans the bronchi, decreases dyspnea, and improves lung functionality. (Anna M Sadowska, 2006) Increases mucociliary clearance by augmenting ciliary motility in chronic obstructive pulmonary. (Sumit Roy Tapadar, 2014)